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ABSTRACT 
 
The vitamin D receptor (VDR) gene is expressed in breast tissue and known to modulate the rate of cell proliferation; HER-2 
proteins are receptors on breast cells which normally help control how a healthy breast cell grows. This study was carried out to 
determine the Immunohistochemical Correlation between the Expression of Vitamin D Receptor (VDR) and Human Epidermal 
Growth Factor Receptor (HER-2) in Invasive Ductal Carcinoma (IDC) tissues. A total number of fifty-six (56) archived female 
breast Invasive Ductal Carcinoma tissue blocks were used. The tissue blocks were sectioned at not more than 2µm each. 
Haematoxylin and Eosin staining method and immunohistochemical staining technique using VDR and HER-2 antibodies were 
done and the results were correlated. The results show that there is a significant difference (P<0.05) found comparing the 
immunohistochemical expression of VDR with HER-2 in IDC tissues. VDR antibody cannot be used in substitute to HER-2 
antibody in the immunohistochemical diagnosis of Invasive ductal carcinoma (IDC) of the breast. However, VDR’s strong 
positive expression in IDC tissues may indicate its links with breast cancer. Therefore, VDR may be recommended as an 
additional antibody in the diagnosis and breast cancer therapeutics 
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INTRODUCTION 
 
Invasive ductal carcinoma (IDC), also known as infiltrating 
ductal carcinoma, is cancer that began growing in the duct and 
has invaded the fatty tissue of the breast outside of the duct. 
IDC is the most common form of breast cancer, representing 
80 percent of all breast cancer diagnoses (Johns Hopkins, 
2016). Breast cancer is the most frequent cancer among 
women, being a heterogeneous disease, with distinct 
morphologies, metastatic behaviour and therapeutic response 
(Ricardo et al., 2011). Approximately, 90% of breast cancer 
deaths are caused by local invasion and distant metastasis of 
tumor cells (Yifau and Binhua, 2011).  According to (Viale, 
2012), different types of this neoplasm exhibit variable 
histopathological and biological features, different clinical 
outcome and different response to systemic interventions. In 
fact, global gene-expression analyses have provided an 
appealing molecular classification for breast carcinomas, 
which is highly associated with patients' prognosis (Sotiriou et 
al., 2003). In the last decade; a major effort has been made to 
better inform the choice of the systemic treatment for breast 
cancer patients.  
 The calcitriol receptor, also known as the vitamin D 
receptor (VDR) and also known as NR1I1 (nuclear receptor 
subfamily 1, group I, member 1), is a member of the nuclear 
receptor family of transcription factors (Hosoi, 2002). Upon 
activation by vitamin D, the VDR forms a heterodimer with 
the retinoid-X receptor and binds to hormone response 
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elements on DNA resulting in expression or transrepression of 
specific gene products. The VDR not only regulates 
transcriptional responses but also involved in microRNA-
directed post transcriptional mechanisms (Uitterlinden et al., 
2004). In humans, the vitamin D receptor is encoded by the 
VDR gene (Norman, 2007). Glucocorticoids are known to 
decrease expression of VDR, which is expressed in most 
tissues of the body and regulate intestinal transport of calcium, 
Iron and other minerals (Bollag, 2007). Also, it has recently 
been identified that VDR as an additional bile acid receptor 
alongside FXR and may function to protect gut against the 
toxic and carcinogenic effects some endobiotics (Salashor and 
Woodgett, 2002).  Many studies have shown that there is a 
link between vitamin D and breast cancer. Women who have 
breast cancer tend to have low levels of vitamin D in their 
body. Researchers have found how vitamin D might have a 
role in breast cancer.  Vitamin D receptors are found on the 
surface of a cell where they receive chemical signals. By 
attaching themselves to a receptor, these chemical signals 
direct a cell to do something, for example to act in a certain 
way, or to divide or die. There are vitamin D receptors in 
breast tissue, and vitamin D can bind to these receptors. These 
can oncogenes to die or stop growing, and can stop the cancer 
cells from spreading to other parts of the body.  Therefore, it 
is thought that vitamin D may help in protecting against breast 
cancer, by making cells in the breast smarter. However, the 
relationship between breast cancer and vitamin D is complex, 
not fully understood, and is still being studied (Rose et al., 
2013; Wang et al., 2013; Welsh, 2012). 
 Breast cancer is the predominant malignancy where 
oncologists use predictive markers clinically to select 
treatment options, with steroid receptors having been used for 
many years. Immunohistochemistry has taken over as the 
major assay method used for assessing markers (Walker, 
2007). The advent of molecular technology has incorporated 
new biomarkers along with immunohistochemical and serum 
biomarkers. Immunohistochemical markers [Estrogen 
receptor (ER), Progesterone receptor (PR), and Human 
epidermal growth factor receptor 2 (HER-2)] are often used to 
guide treatment decisions, to classify breast cancer into 
subtypes that are biologically distinct and behave differently, 
and both as prognostic and predictive factors (Walker, 2007).  
 The HER2 gene makes HER-2 proteins. HER2 proteins 
are receptors on breast cells. Normally, HER2 receptors help 
control how a healthy breast cell grows, divides, and repairs 
itself. But in about 25% of breast cancers, the HER2 gene 
doesn't work correctly and makes too many copies of itself 
(known as HER2 gene amplification) (Breastcancer.org, 
2017). HER2-positive breast cancer is a breast cancer that tests 
positive for a protein called human epidermal growth factor 
receptor 2 (HER2), which promotes the growth of cancer cells 
(Mayoclinic, 2017). VDR polymorphisms are associated with 
breast cancer risk and may be associated with disease 
progression (Guy et al., 2004). The vitamin D receptor (VDR) 
gene is expressed in breast tissue and known to modulate the 
rate of cell proliferation (Buyru et al., 2003). However, the 
correlation between VDR and her2 has not been confirmed by 
any study. This research therefore correlates the 
immunohistochemical expression of VDR with HER-2 in IDC 
tissues. 
MATERIALS AND METHODS 
 
Area of Study 
This study was carried out at Department of Histopathology, 
National Hospital Abuja, FCT, Nigeria. The Hospital serves 
most of the states of Nigeria and therefore serving a significant 
population of the region.  
 
Ethical Standards 
The appropriate ethics committee approved all studies and 
carried out in accordance with 1964 Declaration of Helsinki 
ethical standards. All persons gave their informed consent 
prior to their inclusion in the study.  
 
Sample Size 
A total of fifty-six (56) samples were used. Sample size was 
determined using a formula by (Naing et al., 2006). 
 
Sample Collection/Histopathological Procedures 
Paraffin tissue blocks diagnosed of invasive ductal carcinoma 
of the female breast were used. The tissue blocks were 
sectioned at not more than 2µm each. From each block were 
obtained five sections in which one (1) section was used for 
Haematoxylin and Eosin staining technique while two (2) 
sections were treated each with VDR and HER-2 antibodies, 
while the other two (2) sections were used as negative and 
positive control.  
 
Haematoxylin and Eosin Staining Technique 
The sections were taken to water, stained using Harris 
Haematoxylin for 5minutes, washed in tap water then 
differentiated in 1% acid alcohol for few seconds. They were 
washed in tap water then blued in tap water for 10minutes. The 
sections were then counterstained in 1% Eosin for 1minutes. 
They were then washed in tap water, dehydrated, cleared and 
mounted using DPX (Avwioro, 2014). 
 
Immunohistochemical Technique  
The method used is the Avidin Biotin Complex (ABC) method 
and the antibodies used are manufactured by Novocastra. The 
antibody dilution factor used was 1:100 dilutions for all the 
antibody markers. 
 The processed tissues were sectioned at 2µm on the rotary 
microtome and placed on the hot plate at 700C for at least 
1hour. Sections were brought down to water by passing them 
in 2 changes of Xylene, then 3 changes of descending grades 
of alcohol and finally to water. Antigen retrieval was 
performed on the sections by heating them on a Citric Acid 
solution of pH 6.0 using the Microwave at 1000C for 
15minutes. The sections were equilibrated gradually with cool 
water to displace the hot Citric Acid for at least 5min. 
Peroxidase blocking was done on the sections by covering 
them with 3% hydrogen peroxide (H2O2) for 15min. Sections 
were washed with PBS and protein blocking was performed 
using avidin for 15min. Sections were washed with PBS and 
endogenous biotin in tissue was blocked using biotin for 
15min. After washing with PBS sections were incubated with 
the respective diluted primary antibody antibody diluted 1:100 
for 60 min. Excess antibodies were washed off with PBS and 
a secondary antibody (link) was applied on section for 15min. 
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Sections were washed and the (label, in this case which is the 
Horseradish Peroxidase HRP) was applied on the sections for 
15min.  A working DAB solution is made up by mixing 1 drop 
(20µl) of the DAB chromogen to 1ml of the DAB substrate. 
This working solution was applied on sections after washing 
off the HRP with PBS for at least 5min. The brown reaction 
began to appear at this moment especially for a positive target. 
Excess DAB solution and precipitate were washed with water. 
Sections were counterstained with Haematoxylin solution for 
at least 2min and blued briefly. Sections were dehydrated in 
alcohol, cleared in Xylene and mounted in DPX (Marc, 2009). 
 
Immunohistochemical Analysis 
Cells with specific brown colours in the cytoplasm, cell 
membrane or nuclei depending on the antigenic sites were 
considered to be positive. The Haematoxylin stained cells 
without any form of brown colours were scored negative. 
Nonspecific binding/brown artifacts on cells and connective 
tissue were disregarded (Marc, 2009). 
 
Statistical Analysis 
Photomicrograph was basically used for correlating the 
expression and where necessary, Paired T-test statistics 
method was used to analyse the data generated. 
 
RESULTS 
 
A total of fifty-six (56) tissue blocks already diagnosed as 
invasive ductal carcinoma of the female breast (Age 
mean=46.4) were used for the study. The results ae presented 
in Tables 1 & 2, and in Fig. 1-7. 
 
Table 1:  
Expression of VDR and HER-2 in invasive Ductal 
Carcinoma (IDC)  
Parameter            VDR              HER-2 
Postive                      37                     15               
Negative                   19                     41 
Total                         56                     56      
 
 
Fig. 1:   
Invasive Ductal Carcinoma (IDC)  of the breast  showing 
proliferation of epithelial cells  appearing as atypical cells with 
marked nuclear enlargement and hypercromasia (H and E; x400) 
 
 
Fig. 2:  
Invasive Ductal Carcinoma (IDC) tissue showing Positive 
expression of Vitamin D Receptor (VDR) (x400) 
 
 
Plate 3:  
Invasive Ductal Carcinoma (IDC) tissue showing Negative 
expression of Vitamin D Receptor (VDR)  (x100) 
 
 
 
Plate 4:  
Invasive Ductal Carcinoma (IDC) tissue showing Positive expression 
of HER-2 x400   
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Table 2:  
Correlation of Immunohistochemical Expression between 
VDR and HER-2 In IDC tissues (Paired t-Test) 
 Paired 
Samples 
Statistics 
Mean N SD SEM 
Pair 1 HER-2  
VDR 
1.55 56 0.502 0.067 
 1.34 56 0.478 0.064 
Paired samples 
Correlation 
N Correlation sig  
 HER-2  
VDR 
56 .008 .956  
The mean ± SEM are 0.393 ± 0.087, therefore there is a significant 
difference/relationship between HER2 and VDR at a significant level 
(P)=0.001<0.05, t55= 4.511, Pearson(r)= 0.956  
 
 
 
Plate 5 
Invasive Ductal Carcinoma (IDC) tissue showing Negative 
expression of HER2 (x400) 
 
 
Plate 6:  
Positive Control x400 
 
DISCUSSION 
 
There were significant differences between VDR with HER-2 
expressions in IDC tissues which indicate that VDR cannot be 
used over HER-2 in the immunohistochemical diagnosis of 
IDC. This result is supported by earlier related study done by 
(Friedrich et al., 2002) on VDR expression analyzed 
immunohistochemically in breast cancer patients who 
reported that no statistically significant correlations were 
found comparing VDR expression with expression of estrogen 
receptors (ER) or progesterone receptors (PR), even with the 
proliferation marker Ki-67, with the tumor suppressor gene 
p53 or with the S-phase index. The findings indicate that VDR 
protein expression is not a prognostic factor in breast cancer 
(Friedrich et al., 2002).  
 
 
 
Plate 7:  
Negative Control x400 
 
 VDR shows the highest and strong positive expression on 
IDC tissues in this research which could indicate a link 
between Vitamin D receptor and breast cancer. This support a 
study carried out in which a strong VDR immunoreactivity 
was observed in breast cancer specimens, supporting the body 
of evidence that breast cancer may be a target for 
therapeutically applied vitamin D analogues (Friedrich et al., 
2002; Fasogbon et al., 2017).  
  This also support a study carried out that said; there are 
vitamin D receptors in breast tissue, and vitamin D can bind 
to these receptors. This can cause oncogenes to die or stop 
growing, and can stop the cancer cells from spreading to other 
parts of the body.  Therefore, it is thought that vitamin D may 
help in protecting against breast cancer (Rose et al., 2013). 
 On the basis of this study and review of relevant literature 
it is concluded that VDR has no statistically significant 
correlations when compared with HER-2 antibodies; But 
VDR the highest rate positivism in IDC tissues can indicate it 
links with breast cancer. Therefore, VDR can be 
recommended as an additional antibody in the diagnosis and 
breast cancer therapeutics. 
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